GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (FRA:4AJ0) » Definitions » Gross Margin %

Alk-Abello AS (FRA:4AJ0) Gross Margin % : 63.10% (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Alk-Abello AS Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Alk-Abello AS's Gross Profit for the three months ended in Jun. 2024 was €116.2 Mil. Alk-Abello AS's Revenue for the three months ended in Jun. 2024 was €184.1 Mil. Therefore, Alk-Abello AS's Gross Margin % for the quarter that ended in Jun. 2024 was 63.10%.


The historical rank and industry rank for Alk-Abello AS's Gross Margin % or its related term are showing as below:

FRA:4AJ0' s Gross Margin % Range Over the Past 10 Years
Min: 56.02   Med: 61.53   Max: 69.75
Current: 63.42


During the past 13 years, the highest Gross Margin % of Alk-Abello AS was 69.75%. The lowest was 56.02%. And the median was 61.53%.

FRA:4AJ0's Gross Margin % is ranked better than
52.79% of 754 companies
in the Biotechnology industry
Industry Median: 60.875 vs FRA:4AJ0: 63.42

Alk-Abello AS had a gross margin of 63.10% for the quarter that ended in Jun. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Alk-Abello AS was 2.40% per year.


Alk-Abello AS Gross Margin % Historical Data

The historical data trend for Alk-Abello AS's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Gross Margin % Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.79 58.09 61.18 61.87 62.91

Alk-Abello AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.29 61.71 62.75 65.80 63.10

Competitive Comparison of Alk-Abello AS's Gross Margin %

For the Biotechnology subindustry, Alk-Abello AS's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Gross Margin % falls into.



Alk-Abello AS Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Alk-Abello AS's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=407.2 / 647.218
=(Revenue - Cost of Goods Sold) / Revenue
=(647.218 - 240.023) / 647.218
=62.91 %

Alk-Abello AS's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=116.2 / 184.096
=(Revenue - Cost of Goods Sold) / Revenue
=(184.096 - 67.931) / 184.096
=63.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Alk-Abello AS  (FRA:4AJ0) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Alk-Abello AS had a gross margin of 63.10% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Alk-Abello AS Gross Margin % Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello AS Headlines

No Headlines